Presenilin-1, mutated in familial Alzheimer's disease, maintains genome stability via a γ-secretase dependent way.


Journal

DNA repair
ISSN: 1568-7856
Titre abrégé: DNA Repair (Amst)
Pays: Netherlands
ID NLM: 101139138

Informations de publication

Date de publication:
11 2023
Historique:
received: 08 05 2023
revised: 26 09 2023
accepted: 29 09 2023
medline: 23 10 2023
pubmed: 8 10 2023
entrez: 7 10 2023
Statut: ppublish

Résumé

Mutations in Presenilin-1 (PS1) account for over 80 % mutations linked to familial Alzheimer's disease (AD). However, the mechanisms of action of PS1 mutations in causing familial AD are not fully understood, limiting opportunities to develop targeted disease-modifying therapies for individuals carrying PS1 mutation. To gain more comprehensive insights into the impact of PS1 mutations on genome stability, we knocked down PS1 in SH-SY5Y, HMC3 and A549 cells. This revealed that PS1 knockdown (KD) dramatically induces genome instability (GIN) in all cell types, as indicated by the increased incidence of micronuclei, nucleoplasmic bridges and/or nuclear buds. Although amyloid β (Aβ) was able to induce GIN, PS1-KD was associated with decreased expression of Aβ in SH-SY5Y cells, suggesting Aβ is not the primary cause of GIN in PS1-KD cells. In contrast, inhibiting the PS1 γ-secretase activity by DAPT recapitulated GIN phenotype as seen in PS1-KD cells, indicating that the induction of GIN following PS1 KD can be attributed to the loss of γ-secretase activity. PS1 KD or γ-secretase inhibition markedly sensitizes SH-SY5Y to the genotoxicity of mitomycin C. Interestingly, overexpression of the wildtype PS1 dramatically increased GIN in SH-SY5Y. Collectively, our study demonstrates the potential of PS1 and its γ-secretase activity in maintaining genome stability, highlighting a novel potential link between PS1 loss-of-function or gain-of-function mutations and familial AD through GIN. Several mechanisms by which GIN induced by PS1 dys-expression may contribute to AD are discussed.

Identifiants

pubmed: 37804602
pii: S1568-7864(23)00134-9
doi: 10.1016/j.dnarep.2023.103580
pii:
doi:

Substances chimiques

Amyloid Precursor Protein Secretases EC 3.4.-
Amyloid beta-Peptides 0
Presenilin-1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103580

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors state that they no known competing interests.

Auteurs

Xihan Guo (X)

School of Life Sciences, Yunnan Normal University, Kunming, Yunnan 650500, China; The Engineering Research Center of Sustainable Development and Utilization of Biomass Energy, Yunnan Normal University, Kunming, Yunnan 650500, China. Electronic address: guo_xihan@163.com.

Minyan Jiang (M)

School of Life Sciences, Yunnan Normal University, Kunming, Yunnan 650500, China.

Xueqin Dai (X)

Academy of Biomedical Engineering, Kunming Medical University, Kunming 650500, China.

Jie Shen (J)

School of Life Sciences, Yunnan Normal University, Kunming, Yunnan 650500, China.

Xu Wang (X)

School of Life Sciences, Yunnan Normal University, Kunming, Yunnan 650500, China; The Engineering Research Center of Sustainable Development and Utilization of Biomass Energy, Yunnan Normal University, Kunming, Yunnan 650500, China; Yeda Institute of Gene and Cell Therapy, Taizhou, Zhejiang 318000, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH